EP1474104A2 - Granulats stables a la segregation - Google Patents

Granulats stables a la segregation

Info

Publication number
EP1474104A2
EP1474104A2 EP03706404A EP03706404A EP1474104A2 EP 1474104 A2 EP1474104 A2 EP 1474104A2 EP 03706404 A EP03706404 A EP 03706404A EP 03706404 A EP03706404 A EP 03706404A EP 1474104 A2 EP1474104 A2 EP 1474104A2
Authority
EP
European Patent Office
Prior art keywords
particles
granulate
excipient
lactamase inhibitor
lactam antibiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03706404A
Other languages
German (de)
English (en)
Inventor
Franz Xaver Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0017002A external-priority patent/AT500131A1/de
Priority claimed from AT0019202A external-priority patent/AT500132A1/de
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of EP1474104A2 publication Critical patent/EP1474104A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • the present invention relates to pharmaceutical compositions.
  • compositions are frequently used in the form of powder mixtures or granulates, which are filled into single dose units such as plastic tubes, glass bottles, bags or sachets for administration.
  • Powdered active ingredient, and optionally added excipient e.g. which improve the taste or improve accessibility by machine, have to be formulated in such a way that exact dosage in a filling machine, i.e. an even distribution of active ingredient in each part of said composition should be guaranteed.
  • active ingredient may be distributed unevenly over the different particle sizes of the granulate, e.g. one active ingredient may be found predominantly in the fine particles and another active ingredient in the coarse particles.
  • Dry compaction of active ingredients together with excipients, such as binders, may result in hard, densely compacted products, which, when used for administration in a liquid, such as a powder for oral suspension or dry syrup, may only dissolve slowly or may form a suspension only with difficulty. A sediment can even remain, which may have a negative effect on acceptance and patient compliance.
  • the present invention provides a process for the production of a granulate which is stable to segregation consisting of granulate particles comprising at least one ⁇ -lactam antibiotic and one ⁇ -lactamase inhibitor, and optionally at least one pharmaceutically acceptable excipients, in which both the ⁇ -lactam antibiotic and the ⁇ -lactamase inhibitor are distributed evenly over the different particle sizes of the granulate.
  • the present invention provides a process for the production of a granulate which is stable to segregation consisting of granulate particles comprising at least one ⁇ -lactam antibiotic and one ⁇ -lactamase inhibitor as active ingredients and optionally at least one pharmaceutically acceptable excipient, the process being characterised by the following steps: a. preparing either
  • - excipient-free agglomerate particles with a bulk density of 0.1 to 1.5 g/cm 3 from said ⁇ -lactam antibiotic or from said ⁇ -lactamase inhibitor or from both, with a portion of less than 1 % v/v of agglomerate particles having a diameter of 500 ⁇ m or greater than 500 ⁇ m, or
  • - granulated particles with a bulk density of 0.1 to 1.5 g/ cm 3 from said ⁇ -lactam antibiotic or from said ⁇ -lactamase inhibitor or from both, with a portion of less than 1% v/v of granulated particles having a diameter of 500 ⁇ m or greater than 500 ⁇ m, or
  • step a. in the form of granulated particles obtained in step a., or - in the form of particles which are non-treated according to step a., and optionally with at least one pharmaceutically acceptable excipient or
  • step a the excipient-free agglomerates or granulated particles from said ⁇ -lactam antibiotic obtained in step a. with particles from said ⁇ -lactamase inhibitor which are non-treated according to step a., and optionally with at least one pharmaceutically acceptable excipient, c. compressing the mixture obtained in step b. to obtain a pressing, and d. breaking up the pressing obtained in step c, to obtain a granulate which is stable to segregation.
  • a granulate which is stable to segregation consisting of granulate particles comprising at least one ⁇ -lactam antibiotic and one ⁇ -lactamase inhibitor and optionally at least one pharmaceutically acceptable excipient produced according to a process of the present invention is hereinafter designated as "a granulate of (according to) the present invention.”
  • Suitable ⁇ -lactam antibiotics are known e.g. from The Merck * Index, 12th Edition (1996) and include antibiotically active penicillins, cephalosporins, monobactams or carbapenems, including their pharmaceutically acceptable salts, solvates such as hydrates, preferably ampicillin e.g. in the form of a hydrate, such as a trihydrate (Merck* no. 628), amoxicillin e.g. in the form of a hydrate, such as a trihydrate (Merck * no. 617), penicillin V, e.g. in the form of a potassium salt (Merck* no.
  • cephalexin in the form of a hydrate, such as a onohydrate (Merck* no. 2021), Ticarcillin (Merck * no. 9568), Cefadroxil (Merck* no. 1963), more preferably ampicillin, amoxicillin, penicillin V, cephalexin.
  • Suitable ⁇ -lactamase inhibitors are ⁇ -lactamase inhibitors which, when combined with one or more of ⁇ -lactam antibiotics, e.g. such as indicated above, may result in improved in vivo activity of the ⁇ -lactam antibiotic, including their pharmaceutically acceptable salts, solvates and hydrates.
  • Such ⁇ -lactamase inhibitors are known e.g.
  • clavulanic acid e.g. in the form of a salt, such as a potassium salt (Merck * no. 2402)
  • tazobactam e.g. in the form of a salt, such as a sodium salt (Merck* no. 9251)
  • sulbactam e.g. in the form of a salt, such as a sodium salt (Merck* no. 9058).
  • Combinations of ⁇ -lactam antibiotic and a ⁇ -lactamase inhibitor include, for example, amoxicillin (in the form of a trihydrate) and clavulanic acid, e.g.
  • a granulate of the present invention contains a ⁇ -lactam antibiotic and a ⁇ -lactamase inhibitor, preferably amoxicillin and clavulanic acid, e.g. in appropriate weight ratios, such as weight ratios of amoxicillin : clavulanic acid of 1 :1 to 30:1 , preferably 2:1 to 20:1 , more preferably 2:1, 4:1, 5:1, 7:1, 8:1, 12:1, 14:1,16:1, 18:1 or 20:1.
  • a “granulate” as used herein is understood to be a coagulation of agglomerates of powdered particles, wherein the particles are held together by electrostatic and/or van-der- Waals cohesive forces.
  • Gramulated particles as used herein are originating from a granulate, e.g. obtainable by breaking up a granulate.
  • Agglomerates as used herein, are understood to be larger structures formed from particles in a liquid or gaseous environment, normally having an average equivalent diameter of 1 ⁇ m to 2000 ⁇ m. The cohesive forces between the particles inside an agglomerate are greater than the cohesive forces between two agglomerates or between agglomerate and powder particles inside a granulate.
  • Agglomerates may, in general, be produced by a method as conventional, e.g. by compressing or by an agglomeration build-up process, or by conventional size enlargement processes, whereby small particles are gathered into larger, permanent aggregates in which the original particles can still be identified. This can be done by e.g. dry methods, where no liquid is used for aggregation (compaction) or by wet methods, where liquid is utilized for agglomeration and followed by a drying process.
  • a granulate (granulated material) may be unambigously distinguished, e.g.
  • An excipient-free agglomerate of a ⁇ -lactam antibiotic or of a ⁇ -lactamase inhibitor which is produced according to the process of the present invention in step a, contains a portion of less than 1% v/v, for example 0.0 % v/v to 0.9 % v/v, such as 0.0 % v/v to 0.5 % v/v, or 0.1 % v/v to 0.9 % v/v of agglomerate particles having a diameter of 500 ⁇ m or greater than 500 ⁇ m, optionally a diameter of equal or higher than 500 ⁇ m and lower than 3000 ⁇ m, having a bulk density of at least 0.1 g/cm 3 , preferably at least 0.30 g/cm 3 , more preferably 0.35 g/cm 3 , such as 0.1 g/cm 3 to 1.5 g/cm 3 , 0.3 g/cm 3 to 0.7 g/cm 3 or 0.4
  • excipient-free agglomerate as used herein is understood to contain no or no significant amounts, e.g. 0% to 5% w/w, preferably 0% o 2% w/w, more preferably 0% to 1 % w/w, such as 0 to 0.1 % w/w of excipient(s), such as excipient(s) as conventional, e.g. binders, disintegrants, etc.
  • excipient-free agglomerate may be produced by appropriate methods, e.g.
  • a granulate for the production of granulated particles produced according to step a. of the present invention may be obtained according to a method as described in WO 02/083129.
  • such granulate may be obtained by moist granulation, e.g. according to, e.g. analogously to, a moist granulation method as conventional, or, preferably, as described below:
  • a ⁇ -lactam antibiotic or a ⁇ -lactamase inhibitor may be used in dry form or in solvent-moist form, preferably in solvent moist form, e.g. comprising an amount of 0 to 5% (w/w) of solvent, e.g. in a form as obtained from its preparation process, preferably in crystalline form.
  • K-clavulanate is most preferably obtained from n-butanol or iso-butanol with or without water as a solvent from its preparation process, e.g. a preparation process as described in WO97/18216, the content of which and the content of literature cited therein is incorporated in the present invention by reference.
  • a granulation liquid may be used to obtain a granulation mass.
  • a granulation liquid includes water or an organic solvent, or an organic solvent mixed with water, preferably water or an organic solvent mixed with water.
  • an organic solvent is preferably an alcohol, including e.g. ethanol, n-butanol, isobutanol, preferably a mixture comprising n-butanol or isobutanol and containing 0.5 to 10% (v/v), e.g. 1.0 to 6% (v/v) of water.
  • a granulation mass appropriate for moist granulation may be obtained by mixing a granulation liquid with a ⁇ -lactam antibiotic or a ⁇ -lactamase inhibitor.
  • the amount of granulating liquid is not critical and the minimum amount of granulating liquid may be easily determined.
  • a granulation mass preferably contains a ⁇ -lactam antibiotic or a ⁇ -lactamase inhibitor, and granulating liquid in an amount of 5% (w/w based on wet mass), preferably of 6% (w/w) to 25% (w/w), preferably to 20% (w/w).
  • the obtained granulation mass is dried and granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor is obtained.
  • the granulation mass is extruded to obtain granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor.
  • the granulation mass is extruded, e.g. according, e.g. analogously, to conventional extruding methods, e.g. at appropriate extrusion temperatures, e.g. including temperatures from room temperature and below, e.g. 0°C to 10°C
  • the obtained extruded mass is dried and granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor is obtained, or the extruded mass is passed through a sieve, preferably the extruded mass s passed through a sieve.
  • a preferred mesh size of the sieve is in the range of 1.0 mm to 4.0 mm, e.g. in the range of 2.0 mm to 3.0 mm.
  • a sieved extruded mass obtained by such a method is dried to obtain granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor.
  • a (sieved) extruded mass may be (further) diminuished, e.g. according to, e.g.
  • the granulation mass or the extruded mass undergoes a drying process.
  • High temperatures may degrade, e.g. a ⁇ -lactamase inhibitor, e.g. clavulanic acid, and suitable drying conditions may be found by preliminary tests.
  • a rapid pre-drying of the granulation mass or (sieved) extruded mass and gentle after-drying is carried out.
  • Pre-drying may be effected by passing a gas, e.g. air, through the mass at temperatures in the range of room temperature and above, e.g.
  • Pre-drying preferably continues until the drying substrate has temperatures at or below room temperature, e.g. 25°C or less, for example 10°C to 25°C, preferably 15°C to 25°C Drying may be carried out according to, e.g. analogously to, a method as conventional, e.g. by convection drying such as vacuum drying or dry-air drying. Suitable drying operations are effected as conventional such as by fluidized bed drying or by conveyor-belt-drying, e.g. in a shelf-dryer, a tray-dryer or a chamber-dryer.
  • Pre-drying is preferably effected by belt drying or fluidised bed drying, more preferably fluidised bed drying.
  • dry-air drying is preferably used.
  • Granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor is obtained upon drying.
  • Granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor optionally may be broken up to obtain granulated K-clavulanate (particles) with a desired particle size, e.g. having a desired distribution of grain size, e.g. according, e.g. analogously, to a method as conventional, e.g. by use of a sieve, mill or a compacting device.
  • a desired distribution of grain size may depend on a desired further processing.
  • no excipient is added during the whole process of moist-granulating in order to obtain excipient-free, granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor particles.
  • a ⁇ -lactam antibiotic or a ⁇ -lactamase inhibitor in the form of granulated particles may be prepared according to a process comprising the steps: a. moistening a ⁇ -lactam antibiotic or a ⁇ -lactamase inhibitor with a granulating liquid to obtain a granulation mass, b. optionally extruding the granulation mass obtained to form an extruded mass, c. optionally passing, e.g. pressing, the extruded mass through a sieve, d. drying the granulation mass or (sieved) extruded mass, and e. diminuishing the size grain of of the granulate obtained.
  • no excipient is added during said process.
  • Granulated ⁇ -lactam antibiotic or ⁇ -lactamase inhibitor may have advantageous processing properties, including high bulk densities, e.g. 0.1 to 1.5 g/ cm 3 , preferably 0.5 to 0.8 g/ cm 3 , such as 0.6 to 0.7 g/ cm 3 , for example 0.61 to 0.7 g/cm 3 .
  • "Hydrophobised granulated particles” as used herein are to be understood as granulated particles of a ⁇ -lactamase inhibitor, e.g.
  • granulated clavulanate particles which are protected from rapid dissolution in aqueous liquids at pH values that are different from those at the site of activity, with the result that degradation of the ⁇ -lactamase inhibitor, e.g. K-clavulanate, may be reduced or prevented in aqueous compositions.
  • Such protection may be obtained by treating granulated particles with an oil and a hydrophobic solid, e.g. as described in WO 02/083129.
  • hydrophobised particles practically do not start to dissolve in aqueous liquid, e.g. if clavulanate particles are coated with an oil and a hydrophobic solid.
  • Oils and hydrophobic solids used for hydrophibisation are e.g. as described in WO 02/083129, the content of which is introduced herein by reference.
  • An oil includes pharmaceutically acceptable oils, for example paraffin oils and silicone oils, preferably silicone oils, e.g. silicone oils which have antifoaming characteristics, e.g. siloxanes, such as dimethylpolysiloxane.
  • the oil may be present as such or in a mixture with auxiliaries.
  • auxiliaries include e.g. flow-improving agents, e.g. silicon dioxides, e.g. highly dispersed SiO 2 , such as Aerosil®.
  • Hydrophobic solids include e.g. magnesium stearate.
  • the ratio of amounts of a ⁇ -lactamase inhibitor to oil to hydrophobic solid is not critical.
  • the minimum amount of oil and hydrophobic solid, which prevent dissolving, may be easily determined by preliminary tests.
  • 0.05 g to 0.3 g of oil and 0.05 g to 0.3 g of hydrophobic solid per gram of ⁇ -lactamase inhibitor may be appropriate.
  • Hydrophobised clavulanate may be produced by mixing clavulanate with an oil and a hydrophobic solid.
  • a ⁇ -lactamase inhibitor e.g.
  • clavulanate preferably K-clavulanate
  • clavulanate may be used in a hydrophobisation process in a granulated particle form in which it is obtained by a production process, e.g. such as described above.
  • Mixing may be effected in conventional mixers, e.g. by use of forced-flow mixers.
  • a ⁇ -lactamase inhibitor is pre-mixed with the oil, and the resulting mixture is mixed with the hydrophobic solid.
  • a homogeneous mixture may be and should be obtained.
  • Hydrophobised ⁇ -lactamase inhibitor namely granulated particles comprising a ⁇ -lactamase inhibitor together with an oil and a hydrophobic solid, e.g.
  • ⁇ -Lactamase inhibitor particles coated with a (homogeneous) mixture of the oil and the hydrophobic solid are obtained.
  • ⁇ -Lactamase inhibitor particles should not stick together under the mixing conditions and appropriate non-sticking-conditions may be easily determined, e.g. by preliminary testing.
  • hydrophobised ⁇ -lactamase inhibitor in the form of granulated particles may be stable in aqueous liquids, e.g water, aqueous suspensions, dispersions, salvia, i.e. clavulanate in hydrophobised clavulanate is practically not degraded in aqueous environment.
  • hydrophobised ⁇ -lactamase inhibitor may be still well absorbed within the gastro-intestinal-tract in order to deliberate the ⁇ -lactamase inhibitor at its site of activity, i.e. the bacterial beta-lactamases.
  • the advantageous processing properties of preferably excipient-free, granulated ⁇ -lactamase inhibitor may be maintained after hydrophobisation, e.g. if hydrophobisation is carried out under conditions in which the granulated, hydrophobised ⁇ -lactamase inhibitor particles do not stick together, granulated, hydrophobised ⁇ -lactamase inhibitor particles may maintain high abrasive resistance and high bulk density, e.g. 0.1 to 1.5 g/ cm 3 , preferably 0.5 to 0.8 g/ cm 3 , such as 0.6 to 0.7 g/cm 3 .
  • the hydrophobised ⁇ -lactamase inhibitor particles obtained from such mixing process may be used to produce a granulate according to the present invention.
  • the present invention provides a process according to the present invention, in which process preparation of the excipient-free agglomerates in step a involves the following steps: a21. mixing a solution or suspension of said ⁇ -lactamase inhibitor or of said ⁇ -lactam antibiotic in an appropriate liquid medium with one or more anti-solvents under stirring, a22. isolating excipient-free agglomerates obtained in step a21., which have a grain size portion of less than 1 % by volume of the agglomerate particles with a particle diameter of 500 ⁇ m or more than 500 ⁇ m and a bulk density of 0.1 to 1.5 g/cm 3 , and a23. drying the excipient-free agglomerates obtained in step a22.
  • Steps a21 to a23 may be carried out analogously to the methods disclosed in WO00/41478, e.g. they include appropriate - liquid media in step a21 , for example water, alcohols such as ethanol, methanol,
  • step a21 organic solvents in which the ⁇ -lactam antibiotic or the ⁇ -lactamase inhibitor is insoluble or only poorly soluble, e.g.
  • ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, esters, such as methyl acetate, ethyl acetate, isobutyl acetate, alcohols such as 1-propanol, 1-butanol, 2-butanol, 2-methyl-1-propanol, or a mixture of single indicated anti-solvents.
  • the desired range of particle size of the excipient- free agglomerates may be influenced by agitating (stirring) conditions, e.g. by the rotational speed (and thus shear), tip velocity, power input of the agitator and by the choice and amount of anti-solvent added, and may be adjusted analogously to known methods, e.g. such as indicated in WO00/41478.
  • the agitator may be e.g. a common turbine agitator, pitched blade agitator, toothed disks or rotor-stator mixer, e.g.
  • the ratio between the diameter of the blades versus the diameter of the vessel should be between 0.2 to 0.9, preferably 0.2 to 0.5 depending on the type of agitator.
  • the tip velocity may be in a range of 3 to 15 m/s.
  • Excipient-free agglomerates obtained in in step a23 may be dried according to a method as conventional, e.g. by fluidised bed driers.
  • the present invention provides a process wherein production of the excipient-free agglomerates in step a. involves the following steps: a11. preparing a mass suitable for extrusion consisting of a liquid and particles from said ⁇ -lactam antibiotic or from said ⁇ -lactamase inhibitor, a12. extruding the mass obtained in step a11. with a twin-screw extruder, to obtain an extruded product, a13. drying the extruded product obtained in step a12., and a14. breaking up the dried extruded product of step a13. into excipient-free agglomerates, which have a grain size portion of less than 1% by volume of the agglomerate particles with a particle diameter of 500 ⁇ m or more than 500 ⁇ m and a bulk density of 0.1 to
  • Steps a11. to a13. may be carried out analogously to the process steps described in W097/33564 the content of which is introduced herein by reference.
  • a ⁇ -lactam compound can be kneaded with the assistance of a suitable liquid at 10°C to 80°C to a paste, which is extruded by a twin-screw extruder, after which the extruded products obtained may be dried to produce agglomerates.
  • Suitable liquids for step a11. includes liquid wherein the ⁇ -lactam antibiotic or the ⁇ -lactam inhibitor is insoluble or only begins to dissolve, e.g. water or organic solvents such as alcohols, e.g.
  • step a13. may be carried out by use of drying apparatus as conventional, e.g. fluidised bed driers.
  • drying apparatus as conventional, e.g. fluidised bed driers.
  • W097/33564 it is disclosed that the excipient-free agglomerates of ⁇ -lactam antibiotics, which have the following distribution of grain size, are obtained: ⁇ 100 ⁇ m: 1% to 30% 100 ⁇ m to 500 ⁇ m: 10% to 80% 500 ⁇ m to1000 ⁇ m: 10% to 80%
  • a distribution of grain size of an excipient-free agglomerate with a portion of less than 1% by volume of agglomerate particles greater than 500 ⁇ m is not disclosed in WO97/33564.
  • Breaking up the dried agglomerates in step a14. may take place using appropriate methods, e.g. using a sieve with a mesh size of lower or equal 500 ⁇ m.
  • Excipient-free agglomerates of a ⁇ -lactam compound which are appropriate for the production of a granulate that is stable to segregation according to the present invention have for example an average grain size, based on volume, of 30 ⁇ m, preferably 50 ⁇ m to
  • the bulk density of the excipient-free agglomerates produced according to step a. of the present invention is at least 0.1 g/cm 3 , preferably 0.30 g/cm 3 , more preferably 0.35 g/cm 3 , such as 0.3 g/cm 3 to 0.7 g/cm 3 or 0.4 g/cm 3 to 0.7 g/cm 3 , most preferably 0.5 g/cm 3 to 0.6 g/cm 3 .
  • the bulk density of the granulated particles or the hydrophobised granulated particles produced in step a. of the present invention is at least 0.1 g/cm 3 , preferably between 0.5 g/cm 3 and 0.8 g/cm 3 .
  • the distribution of particle size of an agglomerate or granulate may be determined according to a method as conventional, e.g. by sieving or by a computing procedure (for which the conversion of the type of quantities (e.g. v/v or w/w) must be taken into consideration. If not otherwise indicated, the particle sizes indicated in the present application always refer to the type of quantity of the particle volume (v/v).
  • the bulk density may be determined by a method as conventional, e.g. corresponding to DIN EN 543.
  • a granulate which is stable to segregation, and which can be produced according to the present invention is understood to be a granulate in which all the pharmaceutical active ingredients, such as ⁇ -lactam antibiotics and ⁇ -lactamase inhibitors, are evenly distributed over all grain sizes, i.e. each individual active ingredient in each of the three following grain fractions
  • - below 20% percentile deviates by a maximum of 7% w/w, preferably a maximum of 5% w/w, more preferably a maximum of 3% w/w such as from 0 to 7% w/w, from the portion of ⁇ -lactam antibiotics and ⁇ -lactamase inhibitors which is ideal for the respective grain fraction.
  • the portion of active ingredient which is ideal for the respective grain fraction results from the quotient of the amount of active ingredient in the whole product and the volumetric or mass portion of the grain size fraction in the whole product. If e.g.
  • a granulate exists with quantities of active ingredient totalling 1000 mg amoxicillin and 125 mg of clavulanic acid, then the portion of amoxicillin and clavulanic acid which is ideal for the grain fraction above the 80% percentile - a prerequisite is strict portionality of volume and mass of the granulate - is respectively 20% of the amount of active ingredient in the whole product, that is, 200 mg of amoxicillin and 25 mg of clavulanic acid.
  • the grain fraction below 20% percentile represents the volume or the mass of the 20% smallest particles in the whole product, that above 80% percentile represents the volume or the mass of the 20% largest particles, the grain fraction between 20% percentile and 80% percentile represents the volume or mass of the remaining 60% of all particles in the whole product.
  • Excipients in step b. include conventional, pharmaceutically acceptable excipients, e.g. tabletting excipients, such as fillers, e.g. celluloses, such as Avicel ® , binders such as polyvinyl pyrrolidones, e.g. Polyplasdone®, disintegrants such as modified starches, e.g. Starch 1500 J, Primojel ® , cellulose derivatives, e.g.
  • Excipient(s) may be admixed before, during or after mixing in the second (or further) active ingredient(s), e.g. the ⁇ -lactam antibiotic or the ⁇ -lactamase inhibitor.
  • the whole portion of excipient in the dry compressed tablets, which are obtained according to step c. of the process of the present invention, is preferably less than 100% by weight of the ⁇ -lactam antibiotic.
  • Compression of the mixture obtained in step b. into pressings or compressed tablets in step c. of the process of the present invention may be carried out using appropriate processes, e.g. with tabletting machines.
  • a granulate of the present invention or a granulate produced by a process of the present invention, preferably in association with pharmaceutically acceptable excipient(s), may provide a directly usable pharmaceutical composition.
  • the present invention provides a process for the production of a pharmaceutical composition, comprising adding further pharmaceutically acceptable excipient(s) to a granulate, e.g. admixing with, e.g. to a granulate which is obtained by a process according to the present invention.
  • Excipients which further may be added include e.g. flow-improving agents and lubricants, such as talcum, bentonite, desiccants, such as silicon dioxide, e.g. Aerosil ® , fragrances in order to improve the taste or smell, such as fruit aromas, for example cherry, strawberry, raspberry or vanilla aromas.
  • a pharmaceutical composition of the present invention includes for example
  • suspension granulate e.g. which is filled into suitable, single-dosable units, such as bags or sachets, vials, bottles, plastic tubes, and which may be reconstituted in appropriate liquid, e.g. aqueous liquid, to provide a pharmaceutical, e.g.oral, suspension.
  • suitable, single-dosable units such as bags or sachets, vials, bottles, plastic tubes, and which may be reconstituted in appropriate liquid, e.g. aqueous liquid, to provide a pharmaceutical, e.g.oral, suspension.
  • the present invention provides a process for the production of a pharmaceutical suspension, e.g. oral, comprising at least one ⁇ -lactam antibiotic and one ⁇ -lactamase inhibitor, comprising the steps i. producing a granulate or a pharmaceutical composition of the present invention, and ii. suspending said granulate or composition produced in step i. in aqueous liquid.
  • the aqueous liquid is a drinkable liquid, e.g. water.
  • a pharmaceutical suspension of the present invention may be administered orally.
  • the present invention provides a granulate which is stable to segregation and which contains granulate particles consisting of clavulanic acid and amoxicillin in a weight ratio of 1 :3 to 1 :30 and optionally excipient(s), which is characterised in that both, the clavulanic acid and the amoxicillin, are distributed in such a way that the respective portion thereof in each of the three following grain fractions
  • the present invention provides a pharmaceutical composition, e.g. a dispersible tablet or a(n) (oral) suspension granulate, comprising a granulate of the present invention, optionally together with excipient(s).
  • a pharmaceutical composition e.g. a dispersible tablet or a(n) (oral) suspension granulate, comprising a granulate of the present invention, optionally together with excipient(s).
  • a granulate of the present invention may be used for the preparation of a medicament for treating bacterial infections. It may enable simple handling and more precise dosaging during filling than in the case of known granulates or granulates produced by known methods, even if pneumatic suction devices are used. Such granulates/pharmaceutical compositions can be quickly and completely suspended in an aqueous solution to form a homogeneous suspension, which can have a beneficial effect on acceptance and compliance by patients.
  • %SOLV amount of granulation liquid in %w/w of the total granulation mass. The percentages in parenthesis in the column %SOLV indicate the water portion in %v/v in the granulation liquid
  • K-clavulanate is mixed with the granulating liquid in a mixer with a cooled casing and the granulation mass obtained is dried.
  • K-clavulanate Upon drying K-clavulanate is obtained in granulated form.
  • the granulate obtained is broken over a sieve of mesh size 1 mm.
  • - SOLV granulation liquid, which is used for granulation to obtain the granulation mass
  • %SOLV amount of granulation liquid in %w/w of the total granulation mass. The percentages in parenthesis in the column %SOLV indicate the water portion in %v/v in the granulation liquid
  • K-clavulanate is mixed with n-butanol containing 4% water in a mixer having a cooled casing (3°C) and a granulation mass is obtained.
  • the granulation mass is extruded through an extruder (screw extruder).
  • the extruded mass obtained is dried. Pre-drying is effected in a fluidised bed drier at 30° or 40° air inlet temperature T z until reaching a temperature T G of the dried substrate, and after- drying is carried out by passing through dry air.
  • K-clavulanate is obtained in granulated form. No colouration of granulated K-clavulanate occurs compared with K-clavulanate before granulation and drying. The granulate obtained is broken over a sieve of mesh size 1.0 mm. Results are as set out in TABLE 2 below:
  • K-clavulanate is mixed with n-butanol containing 4% water in a mixer having a cooled casing
  • a granulation mass is obtained and extruded through an extruder (screw extruder).
  • the extruded mass obtained is pressed through a sieve of mesh size 2 mm or 2.5 mm and the sieved extruded mass obtained is dried.
  • Pre-drying is effected in a fluidised bed drier at 30° until reaching a temperature of the dried substrate of 22°, and after-drying is carried out by passing through dry air.
  • K-clavuianate is obtained in granulated form. No colouration of granulated K-clavulanate occurs compared with K-clavulanate before granulation and drying.
  • K-clavulanate is obtained in granulated form with a bulk density in the case of a. is of 0.63 g/ml b. is of 0.64 g/ml, and c. is of 0.67 g/ml.
  • K-clavulanate in granulated form obtained according to a method of examples I, are mixed with 17.9 g of dimethylpolysiloxane and 17.9 g of magnesium stearate in a forced-flow mixer. Particles of K-clavulanate in granulated and hydrophobised form are obtained. Depending on the bulk density of K-clavulanate in granulated form used as a starting material the hydrophobised particles obtained have a granulate-corresponding bulk density of 0.5 to 0.8 g/ml.
  • the hydrophobised clavulanic acid particles are suspended in aqueous liquids (water). Degradation of clavulanic acid in the hydrophobised particles of that suspension was determined and it was found that practically no degradation of clavulanic acid occurred in that aqueous environment.
  • the screws are equipped with conveyor elements, and right- and left-handed kneading blocks.
  • An extruded product obtained is dried on a fluidised bed drier and broken up through a sieve of mesh size 500 ⁇ m.
  • An excipient-free agglomerate of amoxicillin in the form of a trihydrate with the grain size distribution as set out in TABLE 3 is obtained.
  • a mixture obtained is pressed into pressings in a tabletting machine, and broken up over a sieve of mesh size of 1.2 mm. A granulate which is stable to segregation is obtained.
  • TABLE 4 indicates the grain size distribution, the amounts of active ingredient for the individual grain size fractions in an ideal distribution ("ideal” column), the portions of active ingredient determined in the individual grain size fractions ("meas.” column) and the percentage deviation of the values determined from those of the ideal values ("Dev.” column).
  • the deviation of the total amounts from the weighed amounts of active ingredient e.g. 124.6 mg instead of 125 mg clavulanic acid and 980.4 mg instead of 1000 mg of amoxicillin
  • an excipient-free agglomerate is produced, with the difference that the extruded substrate in step A is not sieved.
  • An excipient-free amoxicillin agglomerate is obtained with the grain size distribution as given in TABLE 5.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne un procédé de production d'un granulat qui est stable à la ségrégation et qui comprend des particules granulées, lesquelles renferment au moins une β-lactamine et au moins un inhibiteur de β-lactamase. Ce procédé convient bien pour la fabrication de compositions pharmaceutiques.
EP03706404A 2002-02-01 2003-01-31 Granulats stables a la segregation Withdrawn EP1474104A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AT1702002 2002-02-01
AT0017002A AT500131A1 (de) 2002-02-01 2002-02-01 Organische verbindungen
AT0019202A AT500132A1 (de) 2002-02-06 2002-02-06 Organische verbindungen
AT1922002 2002-02-06
PCT/EP2003/000972 WO2003063820A2 (fr) 2002-02-01 2003-01-31 Granulats stables a la segregation

Publications (1)

Publication Number Publication Date
EP1474104A2 true EP1474104A2 (fr) 2004-11-10

Family

ID=27663978

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03706404A Withdrawn EP1474104A2 (fr) 2002-02-01 2003-01-31 Granulats stables a la segregation

Country Status (3)

Country Link
EP (1) EP1474104A2 (fr)
AU (1) AU2003208358A1 (fr)
WO (1) WO2003063820A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003302381A1 (en) * 2002-11-26 2004-06-18 Lek Pharmaceuticals D.D. Pharmaceutical compositions comprising amoxicillin and clavulanic acid
JP2007523125A (ja) * 2004-02-24 2007-08-16 サンド・アクチエンゲゼルシヤフト アモキシシリンインスタント顆粒
WO2006072577A1 (fr) * 2005-01-07 2006-07-13 Sandoz Ag Procede de preparation de granules comprenant de l’amoxicilline
DE102005061290B4 (de) * 2005-12-20 2021-03-18 Heraeus Medical Gmbh Verfahren zur Herstellung von Antibiotikum-/Antibiotika-Partikeln und deren Verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
ES2201468T3 (es) * 1997-02-14 2004-03-16 Laboratoire Glaxosmithkline S.A.S. Preparacion farmaceutica que comprende amoxicilina y clavulanato.
CN1268888A (zh) * 1997-08-29 2000-10-04 Dsm公司 不含赋形剂的颗粒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO03063820A3 *

Also Published As

Publication number Publication date
WO2003063820A2 (fr) 2003-08-07
AU2003208358A1 (en) 2003-09-02
WO2003063820A3 (fr) 2004-01-15

Similar Documents

Publication Publication Date Title
US20110045082A1 (en) Agglomerates by crystallisation
IE70907B1 (en) Pharmaceutical tablet pharmaceutical granulate and process for their preparation
WO1997031639A1 (fr) COMPRIMES CONTENANT UN ANTIBIOTIQUE AU β-LACTAME ET PROCEDE POUR LEUR PRODUCTION
KR20120101439A (ko) 프로페인-1-설폰산 ｛3-〔5-(4-클로로-페닐)-1ｈ-피롤로〔2,3-ｂ〕피리딘-3-카보닐〕-2,4-다이플루오로-페닐｝-아마이드 조성물 및 그의 용도
JP2000501112A (ja) β―ラクタム化合物を含有する団塊
EP0910344A1 (fr) Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament
JP2001516365A (ja) クラブラネート及び１種以上の賦形剤を含む顆粒
EP1133298B1 (fr) Compositions contenant du cefuroxime axetil
CN112716903B (zh) 一种氨氯地平干混悬剂及其制备方法
CZ293718B6 (cs) Způsob přípravy granulátu obsahujícího orálně účinné beta-laktamové antibiotikum a orální dávkovací forma obsahující orálně účinné beta-laktamové antibiotikum
EP0629404A1 (fr) Composition pharmaceutique contenant du cefditoren pivoxil
EP0958812B1 (fr) Groupe de particules spheriques, son procede de production et produits pharmaceutiques particulaires spheriques constitues desdits groupes de particules
WO2003063820A2 (fr) Granulats stables a la segregation
JPH08291063A (ja) 易吸収性製剤及びその製造法
US20060263424A1 (en) Pharmaceutical compositions comprising clavulanic acid
CN1505512A (zh) 包含托塞米变型ⅱ的稳定药物制剂
CN114652725B (zh) 一种马来酸阿伐曲泊帕环糊精包合物及其药物制剂
EP1349542A1 (fr) Pastilles d'amoxycilline
JP2004002245A (ja) 溶出性を改善したイトラコナゾール経口投与製剤
JP2007131587A (ja) キノリノン誘導体を有効成分とする医薬組成物、及びその製造方法
JPH07291869A (ja) 経口投与用製剤
WO2000066171A1 (fr) Agregat de granules d'alcool de sucre, et procede de preparation correspondant
AT500134A1 (de) Verfahren zur herstellung eines entmischungsstabilen granulats
Mahajan et al. Research Paper Enhanced Dissolution Rate of Glipizide by a Liquisolid Technique
AT500132A1 (de) Organische verbindungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040901

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20070319

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071002